• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Antimicrob Agents Chemother. Fitness Costs for Influenza B Viruses Carrying Neuraminidase Inhibitor-Resistant Substitutions: Underscoring the Importan

Giuseppe

Emeritus
[Source: Antimicrobial Agents and Chemotherapy, full page: (LINK). Abstract, edited.]


Fitness Costs for Influenza B Viruses Carrying Neuraminidase Inhibitor-Resistant Substitutions: Underscoring the Importance of E119A and H274Y

Andrew J. Burnham, Tatiana Baranovich, Bindumadhav M. Marathe, Jianling Armstrong, Robert G. Webster and Elena A. Govorkova*

Author Affiliations: Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place Memphis, Tennessee, 38105-3678, USA


ABSTRACT

Influenza B viruses cause annual outbreaks of respiratory illness in humans and are increasingly recognized as a major cause of influenza-associated pediatric mortality. Neuraminidase (NA) inhibitors (NAIs) are the only available therapy for patients infected with influenza B viruses and the potential emergence of NAI-resistant viruses is a public health concern. The NA substitutions located within enzyme active site could not only reduce NAI susceptibility of influenza B virus but also affect virus fitness. In this study we investigated the effect of single NA substitutions on fitness of influenza B/Yamanashi/166/1998 viruses (Yamagata lineage). We generated recombinant viruses containing either WT NA or NA with a substitution in the catalytic (R371K) or framework residues (E119A, D198E, D198Y, I222T, H274Y, N294S). We assessed NAI susceptibility, NA biochemical properties, NA protein expression, and virus replication in vitro and in differentiated normal human bronchial epithelial (NHBE) cells. Our results showed that four NA substitutions (D198E, I222T, H274Y, and N294S) conferred reduced inhibition by oseltamivir and 3 (E119A, D198Y, and R371K) conferred highly reduced inhibition by oseltamivir, zanamivir, and peramivir. All NA substitutions, except for D198Y and R371K, were genetically stable after 7 passages in MDCK cells. Cell surface NA protein expression was significantly increased by H274Y and N294S substitutions. Viruses with E119A, I222T, H274Y, or N294S substitutions were not attenuated in replication efficiency in vitro or in NHBE cells. Overall, viruses with E119A or H274Y NA substitutions possess fitness comparable to NAI-susceptible virus and their acquisition by influenza B viruses should be closely monitored.


FOOTNOTES

* Correspondence should be addressed to: Elena A. Govorkova, Department of Infectious Diseases, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN 38105-3678; E-mail: elena.govorkova@stjude.org; Tel.: 901-595-2243; Fax: 901-595-8559

Copyright ? 2014, American Society for Microbiology. All Rights Reserved.


-
-------
 
Back
Top Bottom